Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03025542 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
A Phase 2 study of Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 8
- Study locations
NCT03025542: Completed Phase 2 study of Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL.
NCT03025542 is a Phase 2 study of Chronic Plaque Psoriasis that has completed, run by UCB Biopharma SRL. The registered enrollment target is 49 participants, below the 1,124-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03025542, a Phase 2 study of Chronic Plaque Psoriasis, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Primary Outcome
The PASI is the most commonly used and validated assessment for grading the severity of psoriasis in clinical studies. The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The percent area of involvement (BSA%) is estimated across 4 body areas; head (10%), upper limbs (20%), trunk (30%), and lower limbs (40%) and then transferred into a grade. The Investigator assesses the average redness, thickness, and scaliness
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bimekizumab
Study Locations (8)
Other
- Ps0016 102 - Kogarah
- Ps0016 101 - Melbourne
- Ps0016 104 - Woolloongabba
- Ps0016 201 - Ajax
- Ps0016 203 - London
- Ps0016 202 - Windsor
- Ps0016 501 - Chisinau
Ohio
- Ps0016 704 - Bexley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-12-27 |
| Est. Completion | 2017-12-11 |
| Phase | Phase 2 |
What the finished NCT03025542 record still lists
NCT03025542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,124-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03025542 lists 8 locations in 2 states (Other, Ohio).
Frequently Asked Questions
What is clinical trial NCT03025542 about?
NCT03025542 is a clinical study titled "A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis". This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
What is the current status of trial NCT03025542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2016-12-27. Estimated completion is 2017-12-11.
What conditions does trial NCT03025542 study?
This clinical trial studies the following conditions: Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT03025542?
The interventions under investigation include: Placebo (OTHER), Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03025542?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03025542 being conducted?
This trial has 8 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
COMPLETED · Phase 4
-
Chronic Plaque Psoriasis (Ps) Registry
COMPLETED
-
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 4
-
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI